M&A Deal Summary |
|
---|---|
Date | 2021-09-02 |
Target | Hill-Rom |
Sector | Medical Products |
Buyer(s) | Baxter International |
Deal Type | Add-on Acquisition |
Deal Value | 12.4B USD |
Advisor(s) | Goldman Sachs BofA Securities (Financial) Wachtell, Lipton, Rosen & Katz (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1931 |
Sector | Medical Products |
Employees | 60,000 |
Revenue | 14.8B USD (2023) |
Baxter International develops, manufactures and markets drugs and medical products for people with a variety of medical conditions. Baxter's operations are comprised of the BioScience and Medical Products segments. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure. Baxter International was founded in 1931 and is based in Deerfield, Illinois.
DEAL STATS | # |
---|---|
Overall | 20 of 20 |
Sector (Medical Products) | 12 of 12 |
Type (Add-on Acquisition) | 14 of 14 |
State (Illinois) | 1 of 1 |
Country (United States) | 14 of 14 |
Year (2021) | 2 of 2 |
Size (of disclosed) | 1 of 17 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-07-29 |
CryoLife - PerClot Polysaccharide Hemostatic System Certain Assets
Kennesaw, Georgia, United States CryoLife's PerClot Polysaccharide Hemostatic System Certain Assets are indicated for use in surgical procedures (except neurological and ophthalmic) or injuries as an adjunct hemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical. CryoLife's PerClot Polysaccharide Hemostatic System Certain Assets are based in Kennesaw, Georgia. |
Buy | $61M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-05-08 |
Simtra BioPharma Solutions
Deerfield, Illinois, United States Simtra BioPharma Solutions partners with pharmaceutical companies to support their commercialization objectives by providing scientific expertise, sterile contract manufacturing solutions, parenteral delivery systems, and customized support services needed to meet the unique challenges that parenteral products face. Simtra BioPharma Solutions is based in Deerfield, Illinois. |
Sell | $4.3B |